Inflectra® | Safety Profile & Efficacy

Crohn's Disease

In Adults

Inflectra® is indicated for:
• Treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies2.
• Treatment of fistulising, active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy)2.

In Paediatrics

Inflectra® is indicated for treatment of severely active Crohn's disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy2.

 

Click on the boxes below to read more data relating to Inflectra®:

Planetra: Safety and Efficacy in RA
GECSE KB, et al. 2017
PROSIT-BIO: Safety and Efficacy in UC and CD

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

PP-IFA-GBR-0319. December 2018

Planetas: Safety and Efficacy in AS
Study 3.4
Extrapolation of data for all licence indications